KR20220091490A - Pd1 및 vegfr2 이중 결합제 - Google Patents

Pd1 및 vegfr2 이중 결합제 Download PDF

Info

Publication number
KR20220091490A
KR20220091490A KR1020227014433A KR20227014433A KR20220091490A KR 20220091490 A KR20220091490 A KR 20220091490A KR 1020227014433 A KR1020227014433 A KR 1020227014433A KR 20227014433 A KR20227014433 A KR 20227014433A KR 20220091490 A KR20220091490 A KR 20220091490A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
ser
sequence comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227014433A
Other languages
English (en)
Korean (ko)
Inventor
윌리엄 제임스 조나단 핀레이
Original Assignee
울트라휴먼 에이트 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 울트라휴먼 에이트 리미티드 filed Critical 울트라휴먼 에이트 리미티드
Publication of KR20220091490A publication Critical patent/KR20220091490A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020227014433A 2019-10-11 2020-10-09 Pd1 및 vegfr2 이중 결합제 Pending KR20220091490A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1914747.9 2019-10-11
GB201914747A GB201914747D0 (en) 2019-10-11 2019-10-11 PD1 and vegfr2 dual-binding agents
GBGB2013180.1A GB202013180D0 (en) 2019-10-11 2020-08-24 Pd1 and vegfr2 dual-binding agents
GB2013180.1 2020-08-24
PCT/EP2020/078427 WO2021069670A1 (en) 2019-10-11 2020-10-09 Pd1 and vegfr2 dual-binding agents

Publications (1)

Publication Number Publication Date
KR20220091490A true KR20220091490A (ko) 2022-06-30

Family

ID=68619556

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227014433A Pending KR20220091490A (ko) 2019-10-11 2020-10-09 Pd1 및 vegfr2 이중 결합제

Country Status (20)

Country Link
US (3) US20240101674A1 (cg-RX-API-DMAC7.html)
EP (3) EP4041763B1 (cg-RX-API-DMAC7.html)
JP (2) JP7689116B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220091490A (cg-RX-API-DMAC7.html)
CN (2) CN121758618A (cg-RX-API-DMAC7.html)
AU (1) AU2020365021B2 (cg-RX-API-DMAC7.html)
CA (2) CA3156096C (cg-RX-API-DMAC7.html)
DK (1) DK4041763T3 (cg-RX-API-DMAC7.html)
ES (1) ES3027238T3 (cg-RX-API-DMAC7.html)
FI (1) FI4041763T3 (cg-RX-API-DMAC7.html)
GB (2) GB201914747D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20250523T1 (cg-RX-API-DMAC7.html)
HU (1) HUE071341T2 (cg-RX-API-DMAC7.html)
IL (1) IL292158A (cg-RX-API-DMAC7.html)
LT (1) LT4041763T (cg-RX-API-DMAC7.html)
PL (1) PL4041763T3 (cg-RX-API-DMAC7.html)
PT (1) PT4041763T (cg-RX-API-DMAC7.html)
RS (1) RS66837B1 (cg-RX-API-DMAC7.html)
SI (1) SI4041763T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021069670A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109053895B (zh) 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
GB201914747D0 (en) 2019-10-11 2019-11-27 Ultrahuman Eight Ltd PD1 and vegfr2 dual-binding agents
CN116143935A (zh) * 2021-11-22 2023-05-23 杭州翰思生物医药有限公司 重组抗体及其应用
CN119654343A (zh) * 2022-08-09 2025-03-18 上海济煜医药科技有限公司 一种靶向pd-1和vegf的抗体及其应用
CN118620082A (zh) * 2023-03-10 2024-09-10 南京维立志博生物科技有限公司 靶向vegf途径和pd-1的双特异性抗原结合蛋白、其组合物和用途
WO2026150132A1 (en) 2025-01-12 2026-07-16 BioNTech SE Combination therapy comprising an rna cancer vaccine and a multispecific binding agent targeting pd-1/pd-l1 and vegf/vegfr for cancer treatment

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
ES2742379T3 (es) * 2012-05-31 2020-02-14 Hoffmann La Roche Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 y antagonistas de VEGF
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
CR20160319A (es) * 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
MA43028B1 (fr) 2015-10-02 2021-09-30 Hoffmann La Roche Anticorps bispécifiques pour pd1 et tim3
CN109893654B (zh) * 2017-12-11 2021-07-27 江苏恒瑞医药股份有限公司 Vegfr抑制剂治疗肿瘤的方法
GB201803745D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
GB201803746D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
CN109053895B (zh) * 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
JP7883848B2 (ja) 2018-11-06 2026-07-02 ジエンス ヘンルイ メデイシンカンパニー リミテッド 腫瘍を治療するための薬物の調製におけるファミチニブと組み合わせた抗pd-1抗体の使用
GB201914747D0 (en) 2019-10-11 2019-11-27 Ultrahuman Eight Ltd PD1 and vegfr2 dual-binding agents

Also Published As

Publication number Publication date
GB201914747D0 (en) 2019-11-27
JP2025134713A (ja) 2025-09-17
US12479920B2 (en) 2025-11-25
JP7689116B2 (ja) 2025-06-05
CN121758618A (zh) 2026-03-31
US20260167726A1 (en) 2026-06-18
FI4041763T3 (fi) 2025-05-15
AU2020365021B2 (en) 2026-08-13
WO2021069670A1 (en) 2021-04-15
EP4671279A3 (en) 2026-06-24
EP4570824A3 (en) 2025-06-25
RS66837B1 (sr) 2025-06-30
US20250243276A1 (en) 2025-07-31
EP4041763B1 (en) 2025-02-26
SI4041763T1 (sl) 2025-08-29
HRP20250523T1 (hr) 2025-07-04
PL4041763T3 (pl) 2025-07-07
US20240101674A1 (en) 2024-03-28
IL292158A (en) 2022-06-01
EP4041763A1 (en) 2022-08-17
AU2020365021A1 (en) 2022-05-26
JP2022553908A (ja) 2022-12-27
ES3027238T3 (en) 2025-06-13
CA3289307A1 (en) 2026-03-02
EP4570824A2 (en) 2025-06-18
DK4041763T3 (da) 2025-05-19
CA3156096A1 (en) 2021-04-15
CA3156096C (en) 2026-03-17
EP4671279A2 (en) 2025-12-31
LT4041763T (lt) 2025-06-10
HUE071341T2 (hu) 2025-08-28
CN114981301A (zh) 2022-08-30
CN114981301B (zh) 2026-04-14
PT4041763T (pt) 2025-05-16
GB202013180D0 (en) 2020-10-07

Similar Documents

Publication Publication Date Title
CN111683970B (zh) C-kit结合剂
US10858435B2 (en) PD1 binding agents
JP7689116B2 (ja) Pd1およびvegfr2二重結合剤
US12415861B2 (en) Anti C-MET antibodies
CN111819201A (zh) Pd1结合剂
AU2019372436A1 (en) Methods of administering anti-TIM-3 antibodies
CN111818972A (zh) 去免疫的抗erbb3抗体
US11655300B2 (en) Colony stimulating factor 1 receptor (CSF1R) antibodies and immunoconjugates thereof
HK40075900A (en) Pd1 and vegfr2 dual-binding agents
HK40075900B (en) Pd1 and vegfr2 dual-binding agents

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701